JP2012523440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012523440A5 JP2012523440A5 JP2012505103A JP2012505103A JP2012523440A5 JP 2012523440 A5 JP2012523440 A5 JP 2012523440A5 JP 2012505103 A JP2012505103 A JP 2012505103A JP 2012505103 A JP2012505103 A JP 2012505103A JP 2012523440 A5 JP2012523440 A5 JP 2012523440A5
- Authority
- JP
- Japan
- Prior art keywords
- indol
- bromo
- chloro
- hydroxypropyl
- cycloheptylacetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 piperidino, morpholino, pyrrolidino, 5H-tetrazolyl propyl Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 150000001602 bicycloalkyls Chemical group 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 230000003412 degenerative effect Effects 0.000 claims 2
- 208000037765 diseases and disorders Diseases 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 208000017194 Affective disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229910017711 NHRa Inorganic materials 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- SFQWCPUWXNABQE-UHFFFAOYSA-N n-(4-bromo-1-methylindol-3-yl)-2-cycloheptylacetamide Chemical compound C12=C(Br)C=CC=C2N(C)C=C1NC(=O)CC1CCCCCC1 SFQWCPUWXNABQE-UHFFFAOYSA-N 0.000 claims 1
- DLTVKHKUMNDDAH-UHFFFAOYSA-N n-(4-bromo-1-methylindol-3-yl)-2-cyclohexylacetamide Chemical compound C12=C(Br)C=CC=C2N(C)C=C1NC(=O)CC1CCCCC1 DLTVKHKUMNDDAH-UHFFFAOYSA-N 0.000 claims 1
- MYGYHZJROGQMBC-UHFFFAOYSA-N n-(4-bromo-1-methylindol-3-yl)-3-cycloheptylpropanamide Chemical compound C12=C(Br)C=CC=C2N(C)C=C1NC(=O)CCC1CCCCCC1 MYGYHZJROGQMBC-UHFFFAOYSA-N 0.000 claims 1
- CMEKOLJCXWMDIX-UHFFFAOYSA-N n-(4-bromo-1-methylindol-3-yl)-3-cyclohexylpropanamide Chemical compound C12=C(Br)C=CC=C2N(C)C=C1NC(=O)CCC1CCCCC1 CMEKOLJCXWMDIX-UHFFFAOYSA-N 0.000 claims 1
- ISSAMEPSMOIHJK-UHFFFAOYSA-N n-(4-chloro-1-methylindol-3-yl)-2-cycloheptylacetamide Chemical compound C12=C(Cl)C=CC=C2N(C)C=C1NC(=O)CC1CCCCCC1 ISSAMEPSMOIHJK-UHFFFAOYSA-N 0.000 claims 1
- OGWPQDTZTLCWMN-UHFFFAOYSA-N n-(4-chloro-1-methylindol-3-yl)-2-cyclohexylacetamide Chemical compound C12=C(Cl)C=CC=C2N(C)C=C1NC(=O)CC1CCCCC1 OGWPQDTZTLCWMN-UHFFFAOYSA-N 0.000 claims 1
- CRTHKMLUELCZJE-UHFFFAOYSA-N n-(4-chloro-1-methylindol-3-yl)-3-cycloheptylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(C)C=C1NC(=O)CCC1CCCCCC1 CRTHKMLUELCZJE-UHFFFAOYSA-N 0.000 claims 1
- OABNVPUYZRLOCL-UHFFFAOYSA-N n-(4-chloro-1-methylindol-3-yl)-3-cyclohexylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(C)C=C1NC(=O)CCC1CCCCC1 OABNVPUYZRLOCL-UHFFFAOYSA-N 0.000 claims 1
- HEMQGUMFWNJOPJ-UHFFFAOYSA-N n-[1-(3-amino-2-hydroxypropyl)-4-bromoindol-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)CN)C=C1NC(=O)CC1CCCCCC1 HEMQGUMFWNJOPJ-UHFFFAOYSA-N 0.000 claims 1
- YEKWPKSJTPUULO-UHFFFAOYSA-N n-[1-(3-amino-2-hydroxypropyl)-4-bromoindol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)CN)C=C1NC(=O)CC1CCCCC1 YEKWPKSJTPUULO-UHFFFAOYSA-N 0.000 claims 1
- PDEOYPPQJJUNGU-UHFFFAOYSA-N n-[1-(3-amino-2-hydroxypropyl)-4-bromoindol-3-yl]-3-cycloheptylpropanamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)CN)C=C1NC(=O)CCC1CCCCCC1 PDEOYPPQJJUNGU-UHFFFAOYSA-N 0.000 claims 1
- MOTOJNXOWKVYCB-UHFFFAOYSA-N n-[1-(3-amino-2-hydroxypropyl)-4-bromoindol-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)CN)C=C1NC(=O)CCC1CCCCC1 MOTOJNXOWKVYCB-UHFFFAOYSA-N 0.000 claims 1
- ZRSPQUBTFYDJPH-UHFFFAOYSA-N n-[1-(3-amino-2-hydroxypropyl)-4-chloroindol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Cl)C=CC=C2N(CC(O)CN)C=C1NC(=O)CC1CCCCC1 ZRSPQUBTFYDJPH-UHFFFAOYSA-N 0.000 claims 1
- RLSLAFGZBRDMCQ-UHFFFAOYSA-N n-[1-(3-amino-2-hydroxypropyl)-4-chloroindol-3-yl]-3-cycloheptylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(CC(O)CN)C=C1NC(=O)CCC1CCCCCC1 RLSLAFGZBRDMCQ-UHFFFAOYSA-N 0.000 claims 1
- VKUZEUVMCUPMPK-UHFFFAOYSA-N n-[1-(3-amino-2-hydroxypropyl)-4-chloroindol-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(CC(O)CN)C=C1NC(=O)CCC1CCCCC1 VKUZEUVMCUPMPK-UHFFFAOYSA-N 0.000 claims 1
- CHOANFGJVZEOFH-UHFFFAOYSA-N n-[4-bromo-1-(1,3-dihydroxypropan-2-yl)indol-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Br)C=CC=C2N(C(CO)CO)C=C1NC(=O)CC1CCCCCC1 CHOANFGJVZEOFH-UHFFFAOYSA-N 0.000 claims 1
- OPNGEBMRRPPJHP-UHFFFAOYSA-N n-[4-bromo-1-(1,3-dihydroxypropan-2-yl)indol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Br)C=CC=C2N(C(CO)CO)C=C1NC(=O)CC1CCCCC1 OPNGEBMRRPPJHP-UHFFFAOYSA-N 0.000 claims 1
- MBXYMPOSQUTDKU-UHFFFAOYSA-N n-[4-bromo-1-(1,3-dihydroxypropan-2-yl)indol-3-yl]-3-cycloheptylpropanamide Chemical compound C12=C(Br)C=CC=C2N(C(CO)CO)C=C1NC(=O)CCC1CCCCCC1 MBXYMPOSQUTDKU-UHFFFAOYSA-N 0.000 claims 1
- LZLCSZIYRMQUMS-UHFFFAOYSA-N n-[4-bromo-1-(1,3-dihydroxypropan-2-yl)indol-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Br)C=CC=C2N(C(CO)CO)C=C1NC(=O)CCC1CCCCC1 LZLCSZIYRMQUMS-UHFFFAOYSA-N 0.000 claims 1
- SVVOELFVCLNEGG-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxyethyl)indol-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Br)C=CC=C2N(CCO)C=C1NC(=O)CC1CCCCCC1 SVVOELFVCLNEGG-UHFFFAOYSA-N 0.000 claims 1
- YROYXIDRTRDMTE-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxyethyl)indol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Br)C=CC=C2N(CCO)C=C1NC(=O)CC1CCCCC1 YROYXIDRTRDMTE-UHFFFAOYSA-N 0.000 claims 1
- YAQUKGTUOXFJJQ-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxyethyl)pyrrolo[2,3-b]pyridin-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Br)C=CN=C2N(CCO)C=C1NC(=O)CC1CCCCCC1 YAQUKGTUOXFJJQ-UHFFFAOYSA-N 0.000 claims 1
- KNOJYDFTQTURPA-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxyethyl)pyrrolo[2,3-b]pyridin-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Br)C=CN=C2N(CCO)C=C1NC(=O)CC1CCCCC1 KNOJYDFTQTURPA-UHFFFAOYSA-N 0.000 claims 1
- WDSFRYRDDZNRFI-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxyethyl)pyrrolo[2,3-b]pyridin-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Br)C=CN=C2N(CCO)C=C1NC(=O)CCC1CCCCC1 WDSFRYRDDZNRFI-UHFFFAOYSA-N 0.000 claims 1
- OFAVBMQFOMTSNS-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxypropyl)indol-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)C)C=C1NC(=O)CC1CCCCCC1 OFAVBMQFOMTSNS-UHFFFAOYSA-N 0.000 claims 1
- IUYJIHUNZJXWLV-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxypropyl)indol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)C)C=C1NC(=O)CC1CCCCC1 IUYJIHUNZJXWLV-UHFFFAOYSA-N 0.000 claims 1
- DGMCKLKRZYXGKX-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxypropyl)indol-3-yl]-3-cycloheptylpropanamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)C)C=C1NC(=O)CCC1CCCCCC1 DGMCKLKRZYXGKX-UHFFFAOYSA-N 0.000 claims 1
- YXCLCFKUJGINNC-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxypropyl)indol-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)C)C=C1NC(=O)CCC1CCCCC1 YXCLCFKUJGINNC-UHFFFAOYSA-N 0.000 claims 1
- YHSFNEREALZUKL-UHFFFAOYSA-N n-[4-bromo-1-(2-hydroxypropyl)pyrrolo[2,3-b]pyridin-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Br)C=CN=C2N(CC(O)C)C=C1NC(=O)CC1CCCCCC1 YHSFNEREALZUKL-UHFFFAOYSA-N 0.000 claims 1
- AADNCGJNLRDGMG-UHFFFAOYSA-N n-[4-bromo-1-(hydroxymethyl)indol-3-yl]-3-cycloheptylpropanamide Chemical compound C12=C(Br)C=CC=C2N(CO)C=C1NC(=O)CCC1CCCCCC1 AADNCGJNLRDGMG-UHFFFAOYSA-N 0.000 claims 1
- JNGLUTOXXKAMJN-UHFFFAOYSA-N n-[4-bromo-1-(hydroxymethyl)indol-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Br)C=CC=C2N(CO)C=C1NC(=O)CCC1CCCCC1 JNGLUTOXXKAMJN-UHFFFAOYSA-N 0.000 claims 1
- RURAJWCFGSAIHX-UHFFFAOYSA-N n-[4-bromo-1-[2-hydroxy-3-(methylamino)propyl]indol-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)CNC)C=C1NC(=O)CC1CCCCCC1 RURAJWCFGSAIHX-UHFFFAOYSA-N 0.000 claims 1
- JXIOLPVODQMGNN-UHFFFAOYSA-N n-[4-bromo-1-[2-hydroxy-3-(methylamino)propyl]indol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Br)C=CC=C2N(CC(O)CNC)C=C1NC(=O)CC1CCCCC1 JXIOLPVODQMGNN-UHFFFAOYSA-N 0.000 claims 1
- IMPXQWGQCWTHPG-UHFFFAOYSA-N n-[4-chloro-1-(1,3-dihydroxypropan-2-yl)indol-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Cl)C=CC=C2N(C(CO)CO)C=C1NC(=O)CC1CCCCCC1 IMPXQWGQCWTHPG-UHFFFAOYSA-N 0.000 claims 1
- HIIVSNPXBZCNEN-UHFFFAOYSA-N n-[4-chloro-1-(1,3-dihydroxypropan-2-yl)indol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Cl)C=CC=C2N(C(CO)CO)C=C1NC(=O)CC1CCCCC1 HIIVSNPXBZCNEN-UHFFFAOYSA-N 0.000 claims 1
- DVTXIRRZDXMDPE-UHFFFAOYSA-N n-[4-chloro-1-(1,3-dihydroxypropan-2-yl)indol-3-yl]-3-cycloheptylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(C(CO)CO)C=C1NC(=O)CCC1CCCCCC1 DVTXIRRZDXMDPE-UHFFFAOYSA-N 0.000 claims 1
- CVXARHQUPAZUEY-UHFFFAOYSA-N n-[4-chloro-1-(1,3-dihydroxypropan-2-yl)indol-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(C(CO)CO)C=C1NC(=O)CCC1CCCCC1 CVXARHQUPAZUEY-UHFFFAOYSA-N 0.000 claims 1
- NDWPJXLFSZNCQI-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxyethyl)indol-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Cl)C=CC=C2N(CCO)C=C1NC(=O)CC1CCCCCC1 NDWPJXLFSZNCQI-UHFFFAOYSA-N 0.000 claims 1
- KZCSGGNZYJERJX-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxyethyl)indol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Cl)C=CC=C2N(CCO)C=C1NC(=O)CC1CCCCC1 KZCSGGNZYJERJX-UHFFFAOYSA-N 0.000 claims 1
- RYSUBWBWGLTRPX-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxyethyl)pyrrolo[2,3-b]pyridin-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Cl)C=CN=C2N(CCO)C=C1NC(=O)CC1CCCCCC1 RYSUBWBWGLTRPX-UHFFFAOYSA-N 0.000 claims 1
- MMERRSUZVKPFDU-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxyethyl)pyrrolo[2,3-b]pyridin-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Cl)C=CN=C2N(CCO)C=C1NC(=O)CC1CCCCC1 MMERRSUZVKPFDU-UHFFFAOYSA-N 0.000 claims 1
- WDGOQXSORIOXEP-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxyethyl)pyrrolo[2,3-b]pyridin-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Cl)C=CN=C2N(CCO)C=C1NC(=O)CCC1CCCCC1 WDGOQXSORIOXEP-UHFFFAOYSA-N 0.000 claims 1
- ZSZGKSFMXPUDOB-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxypropyl)indol-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Cl)C=CC=C2N(CC(O)C)C=C1NC(=O)CC1CCCCCC1 ZSZGKSFMXPUDOB-UHFFFAOYSA-N 0.000 claims 1
- OSSYXOZWCDPUDL-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxypropyl)indol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Cl)C=CC=C2N(CC(O)C)C=C1NC(=O)CC1CCCCC1 OSSYXOZWCDPUDL-UHFFFAOYSA-N 0.000 claims 1
- SFONSAAWBCIDER-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxypropyl)indol-3-yl]-3-cycloheptylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(CC(O)C)C=C1NC(=O)CCC1CCCCCC1 SFONSAAWBCIDER-UHFFFAOYSA-N 0.000 claims 1
- RSXJYBYZMWKNAB-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxypropyl)indol-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(CC(O)C)C=C1NC(=O)CCC1CCCCC1 RSXJYBYZMWKNAB-UHFFFAOYSA-N 0.000 claims 1
- NYDOQLJTXSWCJK-UHFFFAOYSA-N n-[4-chloro-1-(2-hydroxypropyl)pyrrolo[2,3-b]pyridin-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Cl)C=CN=C2N(CC(O)C)C=C1NC(=O)CC1CCCCCC1 NYDOQLJTXSWCJK-UHFFFAOYSA-N 0.000 claims 1
- XMTIJJMTSVLVBM-UHFFFAOYSA-N n-[4-chloro-1-(hydroxymethyl)indol-3-yl]-3-cycloheptylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(CO)C=C1NC(=O)CCC1CCCCCC1 XMTIJJMTSVLVBM-UHFFFAOYSA-N 0.000 claims 1
- CPACRRVJKRXGDW-UHFFFAOYSA-N n-[4-chloro-1-(hydroxymethyl)indol-3-yl]-3-cyclohexylpropanamide Chemical compound C12=C(Cl)C=CC=C2N(CO)C=C1NC(=O)CCC1CCCCC1 CPACRRVJKRXGDW-UHFFFAOYSA-N 0.000 claims 1
- YUPOWXNTYRBUEA-UHFFFAOYSA-N n-[4-chloro-1-[2-hydroxy-3-(methylamino)propyl]indol-3-yl]-2-cycloheptylacetamide Chemical compound C12=C(Cl)C=CC=C2N(CC(O)CNC)C=C1NC(=O)CC1CCCCCC1 YUPOWXNTYRBUEA-UHFFFAOYSA-N 0.000 claims 1
- IJLCBKMUNKBIDV-UHFFFAOYSA-N n-[4-chloro-1-[2-hydroxy-3-(methylamino)propyl]indol-3-yl]-2-cyclohexylacetamide Chemical compound C12=C(Cl)C=CC=C2N(CC(O)CNC)C=C1NC(=O)CC1CCCCC1 IJLCBKMUNKBIDV-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000003959 neuroinflammation Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09005324 | 2009-04-14 | ||
| EP09005324.0 | 2009-04-14 | ||
| PCT/EP2010/053097 WO2010118921A1 (en) | 2009-04-14 | 2010-03-11 | Novel p2x7r antagonists and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012523440A JP2012523440A (ja) | 2012-10-04 |
| JP2012523440A5 true JP2012523440A5 (enExample) | 2013-04-25 |
Family
ID=42167925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012505103A Pending JP2012523440A (ja) | 2009-04-14 | 2010-03-11 | 新規ｐ２ｘ７ｒ拮抗薬およびその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7919503B2 (enExample) |
| EP (1) | EP2243772B1 (enExample) |
| JP (1) | JP2012523440A (enExample) |
| KR (1) | KR20120006547A (enExample) |
| CN (1) | CN102395562A (enExample) |
| AT (1) | ATE541832T1 (enExample) |
| AU (1) | AU2010237302A1 (enExample) |
| BR (1) | BRPI1014902A2 (enExample) |
| CA (1) | CA2758474A1 (enExample) |
| CY (1) | CY1112758T1 (enExample) |
| DK (1) | DK2243772T3 (enExample) |
| EA (1) | EA201101479A1 (enExample) |
| ES (1) | ES2380908T3 (enExample) |
| HR (1) | HRP20120271T1 (enExample) |
| IL (1) | IL215444A0 (enExample) |
| MX (1) | MX2011010810A (enExample) |
| PL (1) | PL2243772T3 (enExample) |
| PT (1) | PT2243772E (enExample) |
| SG (1) | SG175232A1 (enExample) |
| SI (1) | SI2243772T1 (enExample) |
| SM (1) | SMT201200017B (enExample) |
| WO (1) | WO2010118921A1 (enExample) |
| ZA (1) | ZA201108305B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8828966B2 (en) | 2006-10-03 | 2014-09-09 | Claire Mitchell | Method for treatment of macular degeneration by modulating P2Y12 or P2X7 receptors |
| US8815892B2 (en) | 2008-03-25 | 2014-08-26 | Affectis Pharmaceuticals Ag | P2X7R antagonists and their use |
| EP2105164B1 (en) | 2008-03-25 | 2011-01-12 | Affectis Pharmaceuticals AG | Novel P2X7R antagonists and their use |
| EP2386541A1 (en) * | 2010-05-14 | 2011-11-16 | Affectis Pharmaceuticals AG | Novel methods for the preparation of P2X7R antagonists |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| MX2014000894A (es) | 2011-07-22 | 2014-02-27 | Actelion Pharmaceuticals Ltd | Derivados de amidas heterociclicas como antagonistas de receptores p2x7. |
| US20140322193A1 (en) * | 2011-12-02 | 2014-10-30 | Michael Kaleko | Therapies for Disorders of the Cornea and Conjunctiva |
| BR112014017735B1 (pt) * | 2012-01-20 | 2022-06-28 | Idorsia Pharmaceuticals Ltd | Compostos derivados de amida heterocíclicos como antagonistas do receptor de p2x7, composição farmacêutica, e, uso de um composto |
| EP2931717B1 (en) | 2012-12-12 | 2016-12-07 | Actelion Pharmaceuticals Ltd. | Indole carboxamide derivatives as p2x7 receptor antagonists |
| CA2891499C (en) | 2012-12-18 | 2021-07-06 | Actelion Pharmaceuticals Ltd | Indole carboxamide derivatives as p2x7 receptor antagonists |
| CN104918617B (zh) | 2013-01-22 | 2017-05-10 | 埃科特莱茵药品有限公司 | 作为p2x7受体拮抗剂的杂环酰胺衍生物 |
| JP6282017B2 (ja) | 2013-01-22 | 2018-02-21 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体 |
| WO2014182601A1 (en) | 2013-05-08 | 2014-11-13 | Children's Medical Center Corporation | A method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the atp/p2x7r axis) |
| WO2020150417A2 (en) * | 2019-01-17 | 2020-07-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3705175A (en) * | 1969-04-01 | 1972-12-05 | Egyt Gyogyszervegyeszeti Gyar | Indazole-3-carboxylic amides |
| KR20000075681A (ko) | 1997-02-26 | 2000-12-26 | 그레이엄 브레레톤, 레슬리 에드워즈 | 메탈로프로테아제 억제제로서의 후위 히드록사메이트 유도체 |
| ZA988967B (en) | 1997-10-03 | 2000-04-03 | Du Pont Pharm Co | Lactam metalloprotease inhibitors. |
| SE9704546D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704544D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| WO1999065867A1 (en) | 1998-06-17 | 1999-12-23 | Du Pont Pharmaceuticals Company | Cyclic hydroxamic acids as metalloproteinase inhibitors |
| US6239151B1 (en) | 1998-06-26 | 2001-05-29 | Hoffmann-La Roche Inc. | Compounds as inhibitor of tumor necrosis factor alpha release |
| UA59453C2 (uk) | 1998-08-12 | 2003-09-15 | Пфайзер Продактс Інк. | Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ |
| US20040122011A1 (en) | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
| US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
| TR200102911T2 (tr) | 1999-04-09 | 2002-01-21 | Astrazeneca Ab | Adamantan türevleri. |
| SE9901875D0 (sv) | 1999-05-25 | 1999-05-25 | Astra Pharma Prod | Novel compounds |
| SE9904505D0 (sv) | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
| TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
| SE9904652D0 (sv) | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
| SE9904738D0 (sv) | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
| GB0013737D0 (en) | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
| CA2423733A1 (en) | 2000-08-31 | 2003-02-14 | Terukage Hirata | Novel propenohydroxamic acid derivatives |
| JP2004535411A (ja) | 2001-05-25 | 2004-11-25 | ブリストルーマイヤーズ スクイブ カンパニー | マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物 |
| WO2003016248A2 (en) | 2001-08-17 | 2003-02-27 | Bristol-Myers Squibb Company Patent Department | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace) |
| AU2002341715A1 (en) | 2001-09-17 | 2003-04-01 | Bristol-Myers Squibb Company | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) |
| WO2003031431A1 (en) | 2001-10-09 | 2003-04-17 | Bristol-Myers Squibb Company | Cyclic sulfone derivatives as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace) |
| WO2003055856A2 (en) | 2001-10-17 | 2003-07-10 | Bristol-Myers Squibb Company | BICYCLIC LACTAM DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) |
| US20030212056A1 (en) | 2001-11-02 | 2003-11-13 | Jingwu Duan | Beta-sulfone derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) |
| PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
| WO2003042190A1 (en) | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
| SE0103836D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
| WO2003047515A2 (en) | 2001-11-30 | 2003-06-12 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | P2x7 receptor antagonists |
| US7294624B2 (en) | 2001-12-20 | 2007-11-13 | Bristol Myers Squibb Company | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases |
| KR20040096508A (ko) | 2001-12-21 | 2004-11-16 | 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨. | 티로신 유도체 및 ｐ2ｘ7 수용체 모듈레이터로서의 그의용도 |
| AU2003220401A1 (en) | 2002-03-18 | 2003-10-08 | Bristol-Myers Squibb Company | Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases |
| SE0200920D0 (sv) | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| GB0216379D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Compounds |
| US7102008B2 (en) | 2002-08-01 | 2006-09-05 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme |
| US7041693B2 (en) | 2002-10-04 | 2006-05-09 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| US7074810B2 (en) | 2002-10-07 | 2006-07-11 | Bristol-Myers Squibb Company | Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme |
| US7125870B2 (en) | 2002-11-06 | 2006-10-24 | Bristol-Myers Squibb Company | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme |
| PA8591801A1 (es) | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
| JP2006513205A (ja) | 2002-12-31 | 2006-04-20 | ファイザー・プロダクツ・インク | Ｐ２ｘ７受容体のベンズアミド阻害剤 |
| ITMI20030287A1 (it) * | 2003-02-18 | 2004-08-19 | Acraf | Indazolammidi dotate di attivita' analgesica metodo, per |
| SE0300480D0 (sv) | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
| JP4731468B2 (ja) | 2003-05-12 | 2011-07-27 | ファイザー・プロダクツ・インク | Ｐ２ｘ７受容体のベンズアミド阻害剤 |
| GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
| US7132432B2 (en) | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
| CA2528626A1 (en) * | 2003-07-09 | 2005-01-20 | Biolipox Ab | Indoles useful in the treatment of inflammation |
| SE0302035D0 (sv) * | 2003-07-09 | 2003-07-09 | Biolipox Ab | New compound |
| GB0324498D0 (en) | 2003-07-21 | 2003-11-26 | Aventis Pharma Inc | Heterocyclic compounds as P2X7 ion channel blockers |
| SE0302139D0 (sv) | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
| SE0302192D0 (sv) | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
| WO2005019182A1 (en) | 2003-08-20 | 2005-03-03 | Bayer Healthcare Ag | Pyrazolylmethylbenzamide derivatives as p2xt-receptor antagonists |
| GB2422782A (en) | 2003-10-21 | 2006-08-09 | Inspire Pharmaceuticals Inc | Non-nucleotide compositions and method for treating pain |
| WO2005111003A1 (en) | 2004-04-29 | 2005-11-24 | Abbott Laboratories | Amino-tetrazoles analogues and methods of use |
| AU2005258924A1 (en) | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3H-`1,2,4!-triazin-2-YK!benzamide derivatives with P2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid |
| RU2006146675A (ru) | 2004-06-29 | 2008-07-10 | Пфайзер Продактс Инк. (Us) | Способ получения производных 5-[4-(2-гидроксипропил)-3,5-диоксо-4,5-дигидро-3н-[1,2,4] триазин-2-ил] бензамида снятием защиты с промежуточных продуктов, содержащих защищенный гидроксил |
| US7241776B2 (en) | 2004-08-02 | 2007-07-10 | Abbott Laboratories | Cyanoamidine P2X7 antagonists for the treatment of pain |
| SA05260265A (ar) | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
| SE0402925D0 (sv) | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
| US7786115B2 (en) | 2004-12-24 | 2010-08-31 | Astrazeneca Ab | Amide derivatives |
| EP1844003A4 (en) | 2005-01-27 | 2010-09-22 | Astrazeneca Ab | NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR |
| US20060211739A1 (en) | 2005-02-08 | 2006-09-21 | Arturo Perez-Medrano | Use of selective P2X7 receptor antagonists |
| US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| WO2006110516A1 (en) | 2005-04-11 | 2006-10-19 | Abbott Laboratories | Acylhydrazide p2x7 antagonists and uses thereof |
| CA2607541A1 (en) | 2005-05-05 | 2006-12-28 | Medicure International Inc. | Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds |
| WO2007016597A2 (en) | 2005-07-29 | 2007-02-08 | The Regents Of The University Of California | Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy |
| CA2625940A1 (en) | 2005-08-29 | 2007-03-08 | Irma Bernatchez-Lemaire | Use of histogranin and histogranin-like compounds as inhibitors of p2x7 receptor function and as anti-arthritic agents |
| WO2007028022A2 (en) | 2005-09-01 | 2007-03-08 | Renovis, Inc. | Novel compounds as p2x7 modulators and uses thereof |
| CA2627114A1 (en) | 2005-11-07 | 2007-05-18 | Abbott Laboratories | P2x7 receptor antagonists and methods of use |
| CN101304975A (zh) | 2005-11-09 | 2008-11-12 | 艾博特公司 | P2x7受体拮抗剂及其用途 |
| TWI464148B (zh) | 2006-03-16 | 2014-12-11 | Evotec Us Inc | 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途 |
| WO2007109154A2 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| ES2596532T3 (es) | 2006-03-16 | 2017-01-10 | Second Genome, Inc. | Compuestos de bicicloheteroarilo como moduladores de P2X7 y usos de los mismos |
| WO2007109182A2 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| WO2007109201A2 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| EP2001474B1 (en) | 2006-03-16 | 2016-03-09 | Second Genome, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| GB0611154D0 (en) | 2006-06-06 | 2006-07-19 | Glaxo Group Ltd | Novel receptor antagonists and their methods of use |
| US20090149524A1 (en) | 2006-06-06 | 2009-06-11 | Paul John Beswick | N-(Phenylmethyl)-2-(1H-Pyrazol-4-yl) Acetamide Derivatives as P2X7 Antagonists for the Treatment of Pain, Inflammation and Neurodegeneration |
| WO2008005368A2 (en) | 2006-06-30 | 2008-01-10 | Abbott Laboratories | Piperazines as p2x7 antagonists |
| SI2049478T1 (sl) | 2006-07-06 | 2012-08-31 | Glaxo Group Ltd | Substituirani N-fenilmetil-5-okso-prolin-2-amidi kot antagonisti receptorja P2X7 in postopki za njihovo uporabo |
| WO2009023623A1 (en) * | 2007-08-10 | 2009-02-19 | H, Lundbeck A/S | Heteroaryl amide analogues |
| EP2105164B1 (en) * | 2008-03-25 | 2011-01-12 | Affectis Pharmaceuticals AG | Novel P2X7R antagonists and their use |
-
2010
- 2010-03-11 AT AT10156190T patent/ATE541832T1/de active
- 2010-03-11 EP EP10156190A patent/EP2243772B1/en not_active Not-in-force
- 2010-03-11 PT PT10156190T patent/PT2243772E/pt unknown
- 2010-03-11 BR BRPI1014902A patent/BRPI1014902A2/pt not_active IP Right Cessation
- 2010-03-11 MX MX2011010810A patent/MX2011010810A/es active IP Right Grant
- 2010-03-11 JP JP2012505103A patent/JP2012523440A/ja active Pending
- 2010-03-11 SG SG2011075140A patent/SG175232A1/en unknown
- 2010-03-11 DK DK10156190.0T patent/DK2243772T3/da active
- 2010-03-11 KR KR1020117026988A patent/KR20120006547A/ko not_active Withdrawn
- 2010-03-11 CN CN2010800166929A patent/CN102395562A/zh active Pending
- 2010-03-11 SI SI201030020T patent/SI2243772T1/sl unknown
- 2010-03-11 ES ES10156190T patent/ES2380908T3/es active Active
- 2010-03-11 CA CA2758474A patent/CA2758474A1/en not_active Abandoned
- 2010-03-11 PL PL10156190T patent/PL2243772T3/pl unknown
- 2010-03-11 AU AU2010237302A patent/AU2010237302A1/en not_active Abandoned
- 2010-03-11 WO PCT/EP2010/053097 patent/WO2010118921A1/en not_active Ceased
- 2010-03-11 EA EA201101479A patent/EA201101479A1/ru unknown
- 2010-04-12 US US12/758,557 patent/US7919503B2/en not_active Expired - Fee Related
-
2011
- 2011-02-25 US US13/035,614 patent/US8268861B2/en not_active Expired - Fee Related
- 2011-09-27 IL IL215444A patent/IL215444A0/en unknown
- 2011-11-11 ZA ZA2011/08305A patent/ZA201108305B/en unknown
-
2012
- 2012-03-27 HR HR20120271T patent/HRP20120271T1/hr unknown
- 2012-04-04 CY CY20121100340T patent/CY1112758T1/el unknown
- 2012-04-25 SM SM201200017T patent/SMT201200017B/it unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012523440A5 (enExample) | ||
| CA2758474A1 (en) | Novel p2x7r antagonists and their use | |
| CA2395717C (en) | Fused imidazolium derivatives | |
| JP6505023B2 (ja) | Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物 | |
| ME01488B (me) | Derivati oksadiazola i njihovo korišćenje kao potencijatora metabotropnih glutamatnih receptora-842 | |
| JP6592510B2 (ja) | Ｐ２ｘ７調節因子 | |
| MY156747A (en) | Isoxazolo-pyridine derivatives | |
| JP2014037426A5 (enExample) | ||
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| JP2005516067A5 (enExample) | ||
| TNSN07164A1 (en) | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists | |
| JP2019537559A5 (enExample) | ||
| JP2017508733A5 (enExample) | ||
| NZ602395A (en) | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | |
| JP2016540749A5 (enExample) | ||
| JP2008543860A5 (enExample) | ||
| MX2009013885A (es) | Derivados de quinolina fusionados utiles como moduladores de acido gamma-aminobutirico. | |
| HRP20180973T1 (hr) | Supstituirani tiazolski ili oksazolski antagonisti p2x7 receptora | |
| RU2011125314A (ru) | Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в | |
| MX2009008527A (es) | Compuestos de amonio cuaternario y difenilmetilo utiles como antagonistas del receptor muscarinico. | |
| JO2676B1 (en) | Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines | |
| JP2010522731A (ja) | Ｃｒｔｈ２受容体リガンドとしてのキノリン誘導体 | |
| IL204064A (en) | Compounds 4-Formylphiprazine-1-Carboxamidine Efficacy as Muscarinic Receptor Antagonists | |
| JP2012532125A5 (enExample) | ||
| JP2010526801A5 (enExample) |